Daiichi Sankyo

211 Mt. Airy Road
Basking Ridge
New Jersey
07920
United States

Tel: (908) 992-6400

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.

For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

STOCK EXCHANGE: Tokyo Stock Exchange

STOCK SYMBOL: 4568

337 articles with Daiichi Sankyo

Daiichi Sankyo Working with Berkeley Lights' Beacon OptoFluidic Platform for Cell Line Development

10/30/2017

Berkeley Lights announced today a program with Daiichi Sankyo focused on using the Beacon platform to accelerate its cell line development workflow.
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

10/30/2017

Daiichi Sankyo and Glycotope have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo's proprietary ADC tech with Glycotope's investigational tumor-associated TA-MUC1 antibody PankoMab-GEX.
Exelixis Provides Update On Collaborator Daiichi Sankyo, Inc.’s Phase III Clinical Progress With Esaxerenone (CS-3150), Including Positive Top-Line Results And Additional Pivotal Study

9/25/2017
HTG Molecular Diagnostics And Daiichi Sankyo, Inc. Complete Master Services Agreement

4/17/2017
On a Roll: Kite Pharma Bags $250 Million CAR-T Deal From Daiichi Sankyo, Inc., Forms Joint Venture With Fosun Pharma

1/11/2017
Daiichi Sankyo, Inc. Not Proceed With Lung Cancer Study

5/31/2016
Daiichi Sankyo Cuts-and-Pastes for 5-Year Plan: Sister Companies Daiichi Sankyo, Inc. and Asubio Pharma Co., Ltd. Merge

4/1/2015
Charleston Laboratories, Inc. And Daiichi Sankyo Announce Completion Of A Pharmacokinetics Study On CL-108

3/12/2015
Growth Concerns Loom for Daiichi Sankyo on Drug Warning

2/9/2015
Daiichi Sankyo Release: SAVAYSA (edoxaban) Now Available In U.S. Pharmacies

2/9/2015
Daiichi Sankyo, Inc. Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin

2/4/2015
U.S. FDA Approves Daiichi Sankyo, Inc.'s Once-Daily SAVAYSA™ (Edoxaban) Tablets For Reduction Of Stroke Risk In Non-Valvular Atrial Fibrillation And For The Treatment Of Venous Thromboembolism

1/9/2015
FDA Green Lights Daiichi Sankyo's New Anti-Clotting Drug

1/9/2015
Daiichi Sankyo, Inc. Announces Civil Settlement

1/9/2015
Daiichi Sankyo, Inc. Launches New Formulation Of LIXIANA 60 mg Tablets (edoxaban) In Japan

12/8/2014
Ambit Biosciences And Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society of Hematology

12/5/2014
Charleston Laboratories, Inc. And Daiichi Sankyo, Inc. Initiate Two Phase 3 Clinical Trials On Charleston's Lead Product, CL-108

11/20/2014
Daiichi Sankyo, Inc. And Ambit Biosciences Announce Results Of Tender Offer

11/11/2014
FDA Panel Backs Daiichi Sankyo, Inc.'s New A-Fib Drug Savaysa

10/31/2014
FDA Staff Recommends Limited Use Of Daiichi Sankyo, Inc.'s Blood Thinner Edoxaban

10/29/2014